Yolanda Rodriguez-Ramirez, MD
Infectious Disease · Aibonito, PRNPI 1932396934
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,480 of the $11,624 with a category attached, or 81.6%. 7 manufacturers reported payments, led by Johnson & Johnson at 52.3% of the total. Reporting peaked in 2019 at $11,468 and has fallen 98.9% since, to $125 in 2025. Among infectious disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $484.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Janssen Products, LP$5K
- Organogenesis Inc.$143
- Merck$86
- Viiv Healthcare Company$23
- AbbVie$15
- plus $11 from 1 others
What the payments were for
- Speaking & faculty fees$9,48082%
- Travel & lodging$1,43412%
- Food & beverage$7106%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $6,077 |
| Janssen Products, LP | 11 | $5,268 |
| Organogenesis Inc. | 2 | $143 |
| Merck | 2 | $86 |
| Viiv Healthcare Company | 1 | $23 |
| AbbVie | 1 | $15 |
| Theratechnologies Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symtuza$11,039
- PURAPLY WOUND MATRIX$125
How this compares
$11,624 in reported general payments places this provider in the 90th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 29 | $886 |
| Levofloxacin | 25 | $243 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Aibonito
- Carlos Guzman OrtizAibonito$38K
- Juan Lemos RamirezAibonito$946
- Marisel Bosques RosadoHato Rey$247K
- Jorge Santana BagurManati$180K
- Francisco AlvaradoCaguas$69K
- Jorge Bertran-PasarellHato Rey$64K
- Joel Munoz CoreanoBayamon$59K
- Vanessa Olivo EchavarrySan Juan$41K
- Angeles Rodriguez RosaSan Juan$27K
- Miguel Colon PerezSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.